Barclays Maintains Equal-Weight on CRISPR Therapeutics, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Equal-Weight rating on CRISPR Therapeutics (NASDAQ:CRSP) and raises the price target from $61 to $64.
June 01, 2023 | 11:28 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays maintains an Equal-Weight rating on CRISPR Therapeutics and raises the price target from $61 to $64.
The news of Barclays maintaining an Equal-Weight rating on CRISPR Therapeutics and raising the price target from $61 to $64 indicates that the analyst sees potential in the stock but does not expect significant short-term price movement. This is likely to have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100